Study S002027

Safety Evaluation of Adverse Reactions in Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02092597
Acronym: SAFEGUARD
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 42
Start: 2013-10
Primary completion: 2015-10
Lead sponsor: Charles University, Czech Republic
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:Exenatide; DRUG:Linagliptin; DRUG:Gliclazide
Results posted: FALSE

Registered primary outcomes

Heart rate [90 days after treatment initiation]
Gastric evacuation velocity [90 days after treatment initiation]
Blood pressure [90 days after treatment initiation]
Left ventricular ejection fraction [90 days after treatment initiation]
Intimomedial thickness [90 days after treatment initiation]
Pulse wave velocity [90 days after treatment initiation]
Glomerular filtration rate [90 days after treatment initiation]
Tubular function [90 days after treatment initiation]
KIM-1 [90 days after treatment initiation]
Exocrine pancreas function [90 days after treatment initiation]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.